Skip to main content

Table 3 Ongoing asthma therapies concomitant to omalizumab during the observational period by gender

From: Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair® In the Management of Asthma) study

Treatment regimen

Females

(N = 54)

n (%)

Males

(N = 34)

n (%)

p-value*

No ongoing therapies

1 (1.9)

0 (0.0)

0.281

ICS

43 (79.6)

31 (91.2)

 

 ICS only

3 (5.6)

3 (8.8)

 

 ICS/LABA only

33 (61.1)

21 (61.8)

 

 ICS + ICS/LABA

7 (13.0)

7 (20.6)

 

OCS

10 (18.5)

3 (8.8)

 

 ICS/LABA + OCS

5 (9.3)

1 (2.9)

 

 ICS + ICS/LABA + OCS

3 (5.6)

0 (0.0)

 

 ICS + OCS

2 (3.7)

2 (5.9)

 
  1. Only therapies that were ongoing at baseline and at 6 and 12 months were considered.ICS: inhaled corticosteroids; ICS/LABA: fixed combination of ICS and LABA; LABA: long acting beta2-agonists; OCS: oral corticosteroids
  2. *P-value of Fisher exact test treatment regimen (no ongoing therapies, ICS, OCS) vs gender (females, males) is showed